BACKGROUND: Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myeloma patients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization. MATERIAL AND METHODS: Thirty-one patients [25 BM plasma cells (BMPCs), 18 extramedullary tumor plasma cells], of which 12 had paired samples of BM and extramedullary plasma cells and 14 had previous collection of BM, were investigated for the presence of chromosomal aberrations (CHAs): del(17)(p13), del(13)(q14), 14q32 disruption, t(4;14)(p16;q32), t(14;16)(q32;q23), gain(1)(q21), and hyperdiploidy status. RESULTS: Overall, in unrelated samples, t(4;14) was more prevalent in extramedullary plasma cells, and hyperdiploidy was more frequent in BMPCs. In paired samples, there was a higher frequency of del(13)(q14) and 14q32 disruption in BMPCs. Frequency of all studied CHAs was higher in BMPCs of extramedullary patients than in their previous sample collection. CONCLUSION: These data show that plasma cells harbor more aberrations during their transformation into extramedullary form.
BACKGROUND: Extramedullary disease in multiple myelomapatients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myelomapatients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization. MATERIAL AND METHODS: Thirty-one patients [25 BM plasma cells (BMPCs), 18 extramedullary tumor plasma cells], of which 12 had paired samples of BM and extramedullary plasma cells and 14 had previous collection of BM, were investigated for the presence of chromosomal aberrations (CHAs): del(17)(p13), del(13)(q14), 14q32 disruption, t(4;14)(p16;q32), t(14;16)(q32;q23), gain(1)(q21), and hyperdiploidy status. RESULTS: Overall, in unrelated samples, t(4;14) was more prevalent in extramedullary plasma cells, and hyperdiploidy was more frequent in BMPCs. In paired samples, there was a higher frequency of del(13)(q14) and 14q32 disruption in BMPCs. Frequency of all studied CHAs was higher in BMPCs of extramedullary patients than in their previous sample collection. CONCLUSION: These data show that plasma cells harbor more aberrations during their transformation into extramedullary form.
Authors: Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke Journal: Cancer Lett Date: 2020-01-31 Impact factor: 8.679
Authors: Ignacio Español; Marta Romera; María Dolores Gutiérrez-Meca; Maria Del Carmen García; Aurelia Tejedor; Antonio Martínez; Jerónima Ibáñez; Felipe De Arriba; Alfredo Minguela; Teodoro Iturbe; Maria Dolores López Journal: Clin Case Rep Date: 2017-06-22
Authors: Xiang Zhou; Patricia Flüchter; Katharina Nickel; Katharina Meckel; Janin Messerschmidt; David Böckle; Sebastian Knorz; Maximilian Johannes Steinhardt; Franziska Krummenast; Sophia Danhof; Hermann Einsele; K Martin Kortüm; Leo Rasche Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639
Authors: Lourdes Farre; Gabriela Sanz; Neus Ruiz-Xivillé; Manuel Castro de Moura; Juan Francisco Martin-Tejera; Samuel Gonçalves-Ribeiro; Maria Martinez-Iniesta; Monica Calaf; Jose Luis Mosquera; José Ignacio Martín-Subero; Isabel Granada; Manel Esteller; Eva Domingo-Domenech; Fina Climent; Alberto Villanueva; Anna Sureda Journal: Dis Model Mech Date: 2021-07-15 Impact factor: 5.758
Authors: Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour Journal: Br J Haematol Date: 2021-11-02 Impact factor: 8.615